Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria (Q43662701)

25 November 2017

title

Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria (English)

1 reference

25 November 2017

main subject

multiple drug resistance

1 reference

Aurélien Dinh

1

1 reference

25 November 2017

Jérôme Salomon

series ordinal

2

1 reference

25 November 2017

Jean Pierre Bru

series ordinal

3

1 reference

25 November 2017

Louis Bernard

series ordinal

4

1 reference

25 November 2017

publication date

17 December 2011

1 reference

25 November 2017

1 reference

25 November 2017

volume

44

1 reference

25 November 2017

issue

3

1 reference

25 November 2017

page(s)

182-189

1 reference

Antibiotic-resistant bugs in the 21st century--a clinical super-challenge

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

21 January 2018

Fosfomycin trometamol

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Fosfomycin: use beyond urinary tract and gastrointestinal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

A step closer to extreme drug resistance (XDR) in gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Bacterial prostatitis due to Pseudomonas aeruginosa harbouring the blaVIM-2 metallo-{beta}-lactamase gene from Saudi Arabia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Fosfomycin in the treatment of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/00365548.2011.616221

10.3109/00365548.2011.616221

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference